Lynch syndrome (LS) is the most common hereditary cancer predisposition syndrome and confers substantial lifetime risk for colorectal, endometrial, ovarian, gastric, urothelial, and other malignancies. Colonoscopy and risk‐reducing strategies substantially reduce morbidity and mortality; however, international and national guidelines vary widely in scope, recommended surveillance modalities, timing, intervals, and evidence grading. We conducted a scoping review to map and compare cancer surveillance, risk‐reducing surgery, and chemoprevention recommendations for LS and identify areas of consensus, divergence, and evidence gaps.